Recent Investment Analysts’ Ratings Changes for Avalo Therapeutics (AVTX)

Avalo Therapeutics (NASDAQ: AVTX) recently received a number of ratings updates from brokerages and research firms:

• 8/8/2026 – Avalo Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – Avalo Therapeutics was given a new $48.00 price target by Guggenheim. They now have a “buy” rating on the stock.
• 8/7/2026 – Avalo Therapeutics had its price target lowered by HC Wainwright from $35.00 to $30.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Avalo Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/6/2026 – Avalo Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $38.00 price target on the stock.
• 6/30/2026 – Avalo Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/16/2026 – Avalo Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.
• 6/15/2026 – Avalo Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Activity

In other news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider directly owned 51,776 shares of the company’s stock, valued at $931,968. This represents a 2.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is owned by company insiders.

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.